APA (7th ed.) Citation

S, S., S, A., S, B., S, P., M, G., B, M., . . . S, G. (2024). Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-Vaccinated and Breakthrough SARS-CoV-2 Infected Cases. Vaccines, 12(4), . https://doi.org/10.3390/vaccines12040433

Chicago Style (17th ed.) Citation

S, Shengule, Alai S, Bhandare S, Patil S, Gautam M, Mangaonkar B, Gupta S, Shaligram U, and Gairola S. "Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-Vaccinated and Breakthrough SARS-CoV-2 Infected Cases." Vaccines 12, no. 4 (2024). https://doi.org/10.3390/vaccines12040433.

MLA (9th ed.) Citation

S, Shengule, et al. "Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-Vaccinated and Breakthrough SARS-CoV-2 Infected Cases." Vaccines, vol. 12, no. 4, 2024, https://doi.org/10.3390/vaccines12040433.